Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: water for injections; sodium hydroxide; protamine sulfate; phenol; dibasic sodium phosphate heptahydrate; glycerol; metacresol; hydrochloric acid; zinc oxide - for the treatment of insulin dependent diabetic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; protamine sulfate; metacresol; zinc oxide; glycerol; dibasic sodium phosphate heptahydrate; phenol - for the treatment of insulin dependent diabetic patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ketotifen fumarate 345 µg/ml equivalent to ketotifen 250 µg/ml;   - eye drops, solution - 250 mcg/ml - active: ketotifen fumarate 345 µg/ml equivalent to ketotifen 250 µg/ml   excipient: glycerol sodium hydroxide water for injection - treatment and prevention of signs and symptoms of seasonal allergic conjunctivitis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin glargine - solution for injection - 100unit/1ml

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. pregnancy category b. all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. careful monitoring of glucose control is essential in these patients. therefore, female patients should be advised to tell

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin soluble human; insulin isophane human - suspension for injection - 25unit/1ml ; 75unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin isophane human - suspension for injection - 100unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin soluble human; insulin isophane human - suspension for injection - 50unit/1ml ; 50unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin soluble human; insulin isophane human - suspension for injection - 15unit/1ml ; 85unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin soluble human - solution for injection - 100unit/1ml